| Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas. | |
| | |
MedLine Citation:
|
PMID: 18688571 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: We performed a new phase II trial enrolling patients with newly diagnosed high-grade glioma (HGG) to test the efficacy of a weekly alternating temozolomide (TMZ) schedule after surgery and concomitant chemoradiotherapy. METHODS: From January 2005 to January 2007, 34 patients (21 men, 13 women; age range 30-70, mean age 53) were enrolled. There were 32 glioblastoma multiforme and two anaplastic astrocytoma. Each patient after surgery received standard concurrent chemoradiotherapy. After a 4-week break, patients were then to receive 12 cycles of 1-week-on/1-week-off TMZ, with 75 mg/m(2) for the first cycle, 100 mg/m(2) for the second, 125 mg/m(2) for the third, and 150 mg/m(2) from the fourth to the 12th. Hematological toxicity was monitored every week during concomitant chemoradiotherapy and then every 4 weeks. RESULTS: After 12 months from the end of radiotherapy, the overall survival (OS) rate was 59% (20/38), distributed as follows: 60% (18/30) for recursive partitioning analysis (RPA) class 4 patients and 33% (1/3) for RPA class 6 patients; the only RPA class 1 patient was alive and disease free at the time of writing. Median OS was 13 months [95% confidence interval (CI) 11.02-14.98 months]. Hematological toxicity was seen in six patients (18%): grade 1 neutropenia in four, grade 2 thrombocytopenia in one, and grade 4 thrombocytopenia plus grade 1 neutropenia in one. There was one case of opportunistic infection (Pneumocystis carinii pneumonitis). CONCLUSION: The toxicity of the TMZ dose-dense regimen was very low. Results seem to be encouraging for RPA lower classes (patients with good prognostic factors). |
| | |
Authors:
|
Stefano Dall'oglio; Anna D'Amico; Fabio Pioli; Milena Gabbani; Felice Pasini; Maria Grazia Passarin; Andrea Talacchi; Sergio Turazzi; Sergio Maluta |
Publication Detail:
|
Type: Clinical Trial, Phase II; Journal Article Date: 2008-08-08 |
Journal Detail:
|
Title: Journal of neuro-oncology Volume: 90 ISSN: 0167-594X ISO Abbreviation: J. Neurooncol. Publication Date: 2008 Dec |
Date Detail:
|
Created Date: 2008-11-07 Completed Date: 2009-04-09 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8309335 Medline TA: J Neurooncol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 315-9 Citation Subset: IM |
Affiliation:
|
Radiotherapy Department, Ospedale Civile Maggiore, Piazzale A. Stefani 1, 37126 Verona, Italy. stefano.dalloglio@azosp.vr.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Agents, Alkylating / therapeutic use* Brain Neoplasms / classification, drug therapy*, mortality, radiotherapy Dacarbazine / analogs & derivatives*, therapeutic use Dose-Response Relationship, Drug Female Follow-Up Studies Glioma / classification, drug therapy*, mortality, radiotherapy Humans Kaplan-Meiers Estimate Magnetic Resonance Imaging Male Middle Aged Retrospective Studies |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Alkylating; 4342-03-4/Dacarbazine; 85622-93-1/temozolomide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Focal segmental glomerulosclerosis complicating solitary kidney.
Next Document: Radiobiologic response of medulloblastoma cell lines: involvement of beta-catenin?